Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies.
暂无分享,去创建一个
J. Weiss | E. Tanghetti | P. Yamauchi | J. Sugarman | R. Pillai | S. Harris | J. Soung | T. Lin | Gina Martin
[1] A. Gottlieb,et al. Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data , 2017, Journal of the American Academy of Dermatology.
[2] J. Walsh,et al. Comparative Assessment of PASI and Variations of PGA×BSA as Measures of Psoriasis Severity , 2017 .
[3] B. Strober,et al. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. , 2017, Journal of drugs in dermatology : JDD.
[4] A. Reich,et al. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment. , 2017, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[5] S. Feldman,et al. Long‐term adherence to topical psoriasis treatment can be abysmal: a 1‐year randomized intervention study using objective electronic adherence monitoring , 2017, The British journal of dermatology.
[6] Lakshi M. Aldredge,et al. Psoriasis for the primary care practitioner , 2017, Journal of the American Association of Nurse Practitioners.
[7] S. Youn,et al. The Advantage of Cyclosporine A and Methotrexate Rotational Therapy in Long-Term Systemic Treatment for Chronic Plaque Psoriasis in a Real World Practice , 2017, Annals of dermatology.
[8] A. Gottlieb,et al. Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2. , 2017, Journal of drugs in dermatology : JDD.
[9] G. Girolomoni,et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) , 2015, The British journal of dermatology.
[10] J. Gelfand,et al. Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis. , 2015, Journal of the American Academy of Dermatology.
[11] A. Troxel,et al. Patient satisfaction with treatments for moderate‐to‐severe plaque psoriasis in clinical practice , 2014, The British journal of dermatology.
[12] J. Walsh,et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. , 2013, Journal of the American Academy of Dermatology.
[13] L. Misery,et al. Adherence to topical treatment in psoriasis: a systematic literature review , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.
[14] E. Healy,et al. Self‐management experiences in adults with mild–moderate psoriasis: an exploratory study and implications for improved support , 2010, The British journal of dermatology.
[15] Jan D Bos,et al. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. , 2010, The Journal of investigative dermatology.
[16] A. Gottlieb,et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. , 2009, Journal of the American Academy of Dermatology.
[17] Steven R Feldman,et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. , 2008, Journal of the American Academy of Dermatology.
[18] James T. Elder,et al. Psoriasis: epidemiology. , 2007, Clinics in dermatology.
[19] A. Bowcock,et al. Psoriasis: genetic associations and immune system changes , 2007, Genes and Immunity.
[20] S. Yawalkar,et al. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. , 1991, Journal of the American Academy of Dermatology.
[21] G. Herz,et al. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. , 1991, Journal of the American Academy of Dermatology.
[22] F. Urbach,et al. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies. , 1991, Journal of the American Academy of Dermatology.
[23] S. Yawalkar,et al. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. , 1991, Journal of the American Academy of Dermatology.
[24] S. Prawer,et al. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. , 1991, Journal of the American Academy of Dermatology.
[25] H. Mensing,et al. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. , 1991, Journal of the American Academy of Dermatology.